Eric Devroe - 13 Jan 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Reporting relationship: Chief Operating Officer
Issuer ticker: ACRV
Reported as of: 13 Jan 2026
Net transaction value: +$17,218
SEC form: 4
Accepted by SEC: 15 Jan 2026, 16:38:05 UTC
Prior SEC filing: 18 Nov 2025
Next SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam D. Levy, Attorney-in-Fact

Key filing fact

Eric Devroe filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 15 Jan 2026.

Key facts

This page summarizes Eric Devroe's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Jan 2026, 16:38.

Change

Previous filing in this sequence was filed on 18 Nov 2025.
Current net transaction value: +$17,218.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001950573 Primary reporting owner

Devroe Eric

Relationship: Chief Operating Officer
Address: C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
Signature: /s/ Adam D. Levy, Attorney-in-Fact
Signature date: 15 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRV transaction

Common Stock

Purchase

Transaction value: $17,218
Shares: +10,000
Change %: +15%
Price: $1.72
Shares after: 75,308
Date: 13 Jan 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.719 to $1.7268, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.